Drug Approval | November 21, 2025
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The initiative aims to connect startups and tech companies with its business units,
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
_256_384.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Diversifying its portfolio to include late-phase antiviral agent
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Subscribe To Our Newsletter & Stay Updated
